NasdaqCM - Nasdaq Real Time Price • USD
Regulus Therapeutics Inc. (RGLS)
As of 10:13 AM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
--
10,006.0000
Operating Expense
31,109.0000
31,109.0000
28,239.0000
27,816.0000
24,161.0000
Operating Income
-31,109.0000
-31,109.0000
-28,239.0000
-27,816.0000
-14,155.0000
Net Non Operating Interest Income Expense
1,073.0000
1,073.0000
-83.0000
9.0000
-1,575.0000
Pretax Income
-30,036.0000
-30,036.0000
-28,322.0000
-27,807.0000
-15,730.0000
Tax Provision
1.0000
1.0000
1.0000
1.0000
--
Net Income Common Stockholders
-30,037.0000
-30,037.0000
-28,323.0000
-27,808.0000
-15,730.0000
Diluted NI Available to Com Stockholders
-30,037.0000
-30,037.0000
-28,323.0000
-27,808.0000
-15,730.0000
Basic EPS
-1.58
--
-1.86
-3.24
-4.50
Diluted EPS
-1.58
--
-1.86
-3.24
-4.50
Basic Average Shares
18,960.4010
--
15,259.9580
8,569.8540
3,497.7370
Diluted Average Shares
18,960.4010
--
15,259.9580
8,569.8540
3,497.7370
Total Operating Income as Reported
-31,109.0000
-31,109.0000
-28,239.0000
-27,816.0000
-14,155.0000
Total Expenses
31,109.0000
31,109.0000
28,239.0000
27,816.0000
24,161.0000
Net Income from Continuing & Discontinued Operation
-30,037.0000
-30,037.0000
-28,323.0000
-27,808.0000
-15,730.0000
Normalized Income
-30,037.0000
-30,037.0000
-28,323.0000
-27,808.0000
-15,730.0000
Interest Income
1,677.0000
1,677.0000
605.0000
864.0000
233.0000
Interest Expense
604.0000
604.0000
688.0000
855.0000
1,808.0000
Net Interest Income
1,073.0000
1,073.0000
-83.0000
9.0000
-1,575.0000
EBIT
-29,432.0000
-29,432.0000
-27,634.0000
-26,952.0000
-13,922.0000
EBITDA
-29,205.0000
-29,205.0000
-27,512.0000
-26,493.0000
-13,455.0000
Reconciled Depreciation
227.0000
227.0000
122.0000
459.0000
467.0000
Net Income from Continuing Operation Net Minority Interest
-30,037.0000
-30,037.0000
-28,323.0000
-27,808.0000
-15,730.0000
Normalized EBITDA
-29,205.0000
-29,205.0000
-27,512.0000
-26,493.0000
-13,455.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
--
12/31/2020 - 10/9/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ACRV Acrivon Therapeutics, Inc.
9.15
-3.63%
LVTX LAVA Therapeutics N.V.
2.6500
-3.28%
VTYX Ventyx Biosciences, Inc.
4.0850
-3.65%
CLRB Cellectar Biosciences, Inc.
3.0080
-1.70%
ELEV Elevation Oncology, Inc.
3.7500
-3.35%
XBIO Xenetic Biosciences, Inc.
3.9750
+5.16%
ENVB Enveric Biosciences, Inc.
0.9000
-3.64%
TCBP TC Biopharm (Holdings) Plc
1.5500
+5.45%
XLO Xilio Therapeutics, Inc.
1.0350
-2.36%
ELYM Eliem Therapeutics, Inc.
3.5800
-2.18%